A high-risk lesion for invasive breast cancer, ductal carcinoma in situ, exhibits frequent overexpression of retinoid X receptor.

The development of prevention strategies for breast cancer will require a molecular map of carcinogenesis. We have investigated gene expression patterns in premalignant and early carcinomatous human breast lesions that confer to the patient varying risks for developing invasive breast cancer. The relative expression levels of one of the retinoid receptors, retinoid X receptor (RXR), was determined by in situ hybridization to 58 biopsy specimens; RXR mRNA grain density over each lesion was compared to that over the normal ductal/lobular units in each section. Overexpression of RXR mRNA was observed in 66% of noncomedo ductal carcinoma in situ (DCIS), which confer a >8-fold increase in breast cancer risk, and 88% of comedo DCIS lesions, which are associated with a yet higher risk. In contrast, only 8% of lesions that confer little or no increase in breast cancer risk overexpressed RXR mRNA (P = 0.0008). Limited in situ hybridization data using retinoic acid receptor (RAR) riboprobes showed overexpression of RAR alpha, but not RAR beta or -gamma, in only a modest percentage (36%) of cases, suggesting that all members of the retinoid receptor superfamily are not similarly regulated. Immunohistochemistry performed on 52 DCIS specimens for alpha, beta, and gamma isoforms of RXR confirmed its overexpression at the protein level and implicate RXR alpha as the predominant overexpressed form. The data indicate that RXR overexpression is associated with an increased risk for the development of invasive breast cancer in human breast lesions and suggest the hypothesis that it is causally involved in breast oncogenesis. The implications for retinoid chemoprevention are discussed.

[1]  S. Schnitt,et al.  Estrogen receptor immunohistoohemistry in carcinoma in situ of the breast , 2010, Cancer.

[2]  R. Bernards,et al.  CDK-Independent Activation of Estrogen Receptor by Cyclin D1 , 1997, Cell.

[3]  M. Gottardis,et al.  Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. , 1996, Cancer research.

[4]  P. Steeg,et al.  Molecular analysis of premalignant and carcinoma in situ lesions of the human breast. , 1996, The American journal of pathology.

[5]  R. Zeillinger,et al.  Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors , 1996, International journal of cancer.

[6]  G. Peters,et al.  Cyclin D1 and prognosis in human breast cancer , 1996, International journal of cancer.

[7]  J. Peterse,et al.  A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. , 1996, British Journal of Cancer.

[8]  D. Noonan,et al.  Convergence of three steroid receptor pathways in the mediation of nongenotoxic hepatocarcinogenesis. , 1996, Carcinogenesis.

[9]  R. Evans,et al.  The RXR heterodimers and orphan receptors , 1995, Cell.

[10]  M. Merino,et al.  Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions , 1995, Nature Medicine.

[11]  B. Hollis,et al.  Retinoid X Receptor Acts as a Hormone Receptor in Vivo to Induce a Key Metabolic Enzyme for 1,25-Dihydroxyvitamin D3(*) , 1995, The Journal of Biological Chemistry.

[12]  D. Soprano,et al.  Effect of 9-cis-retinoic acid on growth and RXR expression in human breast cancer cells. , 1995, Experimental cell research.

[13]  A. Sugawara,et al.  Evidence that Retinoid X Receptors Mediate Retinoid-dependent Transcriptional Activation of the Retinoic Acid Receptor Gene in S91 Melanoma Cells (*) , 1995, The Journal of Biological Chemistry.

[14]  F. Schmitt,et al.  p53 protein expression and nuclear DNA content in breast intraductal proliferations , 1995, The Journal of pathology.

[15]  L. D. De Luca,et al.  Mouse skin tumor progression results in differential expression of retinoic acid and retinoid X receptors. , 1995, Cancer research.

[16]  E. Schmidt,et al.  Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. , 1995, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[17]  Z. Shao,et al.  Thyroid hormone enhancement of estradiol stimulation of breast carcinoma proliferation. , 1995, Experimental cell research.

[18]  F. Schmitt,et al.  Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c‐erbB‐2 protein , 1995, Cancer.

[19]  J. Bartek,et al.  Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. , 1995, Cancer letters.

[20]  S. Hirohashi,et al.  Pattern of gene alterations in intraductal breast neoplasms associated with histological type and grade. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  A. Klein-Szanto,et al.  Immunohistochemistry of cyclin D1 in human breast cancer. , 1994, American journal of clinical pathology.

[22]  M. Lazar,et al.  Endogenous retinoid X receptors can function as hormone receptors in pituitary cells , 1994, Molecular and cellular biology.

[23]  R. Sutherland,et al.  Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Validire,et al.  Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. , 1994, Seminars in diagnostic pathology.

[25]  W. Dupont,et al.  p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[26]  Emma Lees,et al.  Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice , 1994, Nature.

[27]  Jiri Bartek,et al.  Cyclin D1 protein expression and function in human breast cancer , 1994, International journal of cancer.

[28]  P Chambon,et al.  The retinoid signaling pathway: molecular and genetic analyses. , 1994, Seminars in cell biology.

[29]  J. Bartek,et al.  Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. , 1994, Cancer research.

[30]  Y. Wan,et al.  Dexamethasone increases the expression of retinoid X receptor genes in rat hepatoma cell lines. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[31]  D N Poller,et al.  Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and C-erbB-2 oncogene expression. Nottingham Breast Team. , 1993, Clinical radiology.

[32]  J. A. Hamilton,et al.  Expression and amplification of cyclin genes in human breast cancer. , 1993, Oncogene.

[33]  R. Blamey,et al.  Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein , 1993 .

[34]  S. Hirschfeld,et al.  Inhibition of estrogen-responsive gene activation by the retinoid X receptor beta: evidence for multiple inhibitory pathways , 1993, Molecular and cellular biology.

[35]  P. Lemotte,et al.  RXR-dependent and RXR-independent transactivation by retinoic acid receptors. , 1993, Nucleic acids research.

[36]  K. Keyomarsi,et al.  Redundant cyclin overexpression and gene amplification in breast cancer cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[37]  K. Zedeler,et al.  Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. , 1992, The American journal of surgical pathology.

[38]  T. Ravikumar,et al.  Ten-year follow-up of breast carcinoma in situ in Connecticut. , 1992, Archives of surgery.

[39]  P. Chambon,et al.  Multiplicity generates diversity in the retinoic acid signalling pathways. , 1992, Trends in biochemical sciences.

[40]  W. McGuire,et al.  Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. , 1992, Human pathology.

[41]  K. Umesono,et al.  Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors , 1992, Nature.

[42]  J. Lehmann,et al.  Homodimer formation of retinoid X receptor induced by 9-cis retinoic acid , 1992, Nature.

[43]  H. Thornton,et al.  Ductal carcinoma-in-situ of the breast , 1992, The Lancet.

[44]  T. Bugge,et al.  RXR alpha, a promiscuous partner of retinoic acid and thyroid hormone receptors. , 1992, The EMBO journal.

[45]  E. Appella,et al.  H‐2RIIBP (RXR beta) heterodimerization provides a mechanism for combinatorial diversity in the regulation of retinoic acid and thyroid hormone responsive genes. , 1992, The EMBO journal.

[46]  R. Evans,et al.  Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. , 1992, Genes & development.

[47]  R. Walker,et al.  Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. , 1992, European journal of cancer.

[48]  M. Pfahl,et al.  Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors , 1992, Nature.

[49]  K. Umesono,et al.  Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling , 1992, Nature.

[50]  Gregor Eichele,et al.  9-cis retinoic acid is a high affinity ligand for the retinoid X receptor , 1992, Cell.

[51]  Philippe Kastner,et al.  Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently , 1992, Cell.

[52]  J. Grippo,et al.  9-Cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRα , 1992, Nature.

[53]  C. Glass,et al.  RXRβ: A coregulator that enhances binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elements , 1991, Cell.

[54]  K. Umesono,et al.  A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR , 1991, Cell.

[55]  J. Rottman,et al.  A retinoic acid-responsive element in the apolipoprotein AI gene distinguishes between two different retinoic acid response pathways , 1991, Molecular and cellular biology.

[56]  R. Lotan.  Retinoids as modulators of tumor cells invasion and metastasis. , 1991, Seminars in cancer biology.

[57]  P. Chambon,et al.  Modulation by retinoids of mRNA levels for nuclear retinoic acid receptors in murine melanoma cells. , 1990, Molecular endocrinology.

[58]  D. Weiner,et al.  Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. , 1990, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[59]  R. Evans,et al.  Nuclear receptor that identifies a novel retinoic acid response pathway , 1990, Nature.

[60]  D. Giri,et al.  Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study , 1989, Histopathology.

[61]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[62]  D. Schroeder,et al.  Effects of dietary retinoids upon growth and differentiation of tumors derived from several murine embryonal carcinoma cell lines. , 1988, Cancer research.

[63]  D. Page,et al.  Cancer risk assessment in benign breast biopsies. , 1986, Human pathology.

[64]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.

[65]  M. Altmann,et al.  Chemically induced differentiation of murine embryonal carcinoma in vivo: transplantation of differentiated tumors. , 1984, Cancer research.

[66]  Y. Wan,et al.  The expression of retinoid X receptor genes is regulated by all-trans- and 9-cis-retinoic acid in F9 teratocarcinoma cells. , 1994, Experimental cell research.

[67]  P. T. van der Saag,et al.  Retinoic acid receptor and retinoid X receptor expression in retinoic acid—resistant human tumor cell lines , 1993, Molecular carcinogenesis.

[68]  S. Hirschfeld,et al.  Erratum: Inhibition of estrogen-responsive gene activation by the retinoid X receptor β: Evidence for multiple inhibitory pathways (Molecular and Cellular Biology 13:4 (2258)) , 1993 .

[69]  K. Zedeler,et al.  Ductal carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. , 1992, The American journal of surgical pathology.

[70]  J. Y. Chen,et al.  Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. , 1992, Cell.

[71]  R. Lotan,et al.  Retinoids in the management of melanoma , 1991 .

[72]  O. Haugen,et al.  DNA ploidy in intraductal breast carcinomas. , 1990, European journal of cancer.

[73]  R. Lotan,et al.  Retinoid-sensitive cells and cell lines. , 1990, Methods in enzymology.

[74]  M. Sherman.  Retinoids and cell differentiation , 1986 .